title: Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
abstract: Angiotensin II is a potent vasoconstrictor that stimulates aldosterone secretion. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are currently in use for the treatment of hypertension and chronic heart failure. Clinical trials show ACEIs to be effective, but with significant side effects, while ARBs provide a useful, more well-tolerated, alternative. ARBs are based on the structure of losartan, and efficacy has been enhanced by development of longer-lasting insurmountable antagonists. Combination therapy is another option; however, there is also scope for development of new molecules that exploit our increased understanding of angiotensin receptor structure and function.
authors.affiliation: Queen Mary, University of London, School of Biological Sciences, Mile End Road, London, E1 4NS, UK. s.barker@qmul.ac.uk
authors.forename: Rashmi K
authors.initials: RK
authors.lastname: Singh
authors.forename: Stewart
authors.initials: S
authors.lastname: Barker
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D011945:Receptors, Angiotensin / Q000737:chemistry / Q000378:metabolism
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011945:Receptors, Angiotensin